Clinical trials: Malignant Head and Neck Neoplasm
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
CK-301 (cosibelimab) is a fully human monoclonal antibody of IgG1 subtype that directly binds to Programmed Death-Ligand 1 (PD-L1) and blocks its interactions with the Programmed Death-1 (PD-1) and B7.1 receptors.
- Conditions
- Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell, Malignant Mesothelioma, Advanced
- Trial name
- NCT03212404
- Testing
- CK-301 (cosibelimab)
- Where
- 48 sites in Australia, France and 7 more
- Volunteers
- 272 people
- Sponsor
- Checkpoint Therapeutics, Inc.
Astrocytoma, Brain Cancer
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
This is a multi-center, open-label, dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) of QBS10072S in patients with advanced or metastatic cancers…
- Conditions
- Astrocytoma, Brain Cancer, Brain Metastases, Bladder Cancer
- Trial name
- NCT04430842
- Testing
- QBS10072S
- Where
- 2 sites in Australia
- Volunteers
- 15 people
- Sponsor
- Quadriga Biosciences, Inc.
Adenocarcinoma of the Colon, Adenocarcinoma of the Gallbladder
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
Phase I trial to study the effectiveness of vaccine therapy with or without sargramostim in treating patients who have advanced or metastatic cancer. Vaccines may make the body build an immune response to kill tumor cells.
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Gallbladder, Adenocarcinoma of the Pancreas, Adenocarcinoma of the Rectum
- Trial name
- NCT00028496
- Testing
- recombinant fowlpox-CEA(6D)/TRICOM vaccine, sargramostim, recombinant fowlpox GM-CSF vaccine adjuvant
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced Malignant Neoplasm, Oral Cancer
Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer
EGFR is a potential target for new anticancer therapy in head and neck squamous cell carcinoma, because blocking the EGFR by a monoclonal antibody results in inhibition of the stimulation of the receptor, therefore, in inhibition…
- Conditions
- Locally Advanced Malignant Neoplasm, Oral Cancer, Oropharyngeal Carcinoma, Effects of Chemotherapy
- Trial name
- EAGLE (NCT01434394)
- Testing
- Neo-adjuvant Erbitux-based chemotherapy
- Where
- China
- Volunteers
- 243 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Malignant Tumor of Soft Tissue of Head, Face and Neck
Acupuncture as the Therapeutic Modalities of Acute Toxicity in the Radiotherapy of Head and Neck Tumors
The aim of the study is to evaluate the benefit of the acupuncture as healing modalities in the therapy of acute toxicity of radiotherapy.
- Trial name
- NCT03751566
- Testing
- Acupuncture, Standard supportive therapy
- Where
- Czechia
- Volunteers
- 60 people
- Sponsor
- Masaryk Memorial Cancer Institute
Malignant Neoplasm of Thyroid, Heart Diseases
Thyrotropin Over-suppression and Heart
The investigators evaluated the cardiac effects of Thyroid-stimulating hormone (TSH) over-suppression in women with differentiated thyroid cancer (DTC) frequently encountered during suppression therapy.
- Conditions
- Malignant Neoplasm of Thyroid, Heart Diseases, Thyrotoxicosis on Thyroxine Therapy
- Trial name
- NCT02645786
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Chuncheon Sacred Heart Hospital
Maligant Solid Tumor, Head & Neck Cancer
The Safety, Dosimetry and Efficacy of 177Lu-INN805 in Patients With Malignant Solid Tumors
This study is a prospective, single-arm, open-label, dose-escalation study. A total of 4 dose groups were pre-defined in this study. The drug was administered once every 6 weeks.The drug would be administered for 1 to 4 cycles.
- Conditions
- Maligant Solid Tumor, Head & Neck Cancer, Thyroid Cancer, Lung Cancer - Non Small Cell Squamous
- Trial name
- NCT07459283
- Testing
- INN805
- Where
- China
- Volunteers
- 10 people
- Sponsor
- FindCure Biosciences (ZhongShan) Co., Ltd.
HER2-positive, Adenocarcinoma
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Phase 1, first-in-human, open label study of CAR macrophages in HER2 overexpressing solid tumors.
- Conditions
- HER2-positive, Adenocarcinoma, Bile Duct Cancer, Biliary Tract Cancer
- Trial name
- NCT04660929
- Testing
- CT-0508, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Carisma Therapeutics Inc
Malignant Neoplasm in the Head and Neck, Metastatic Malignant Neoplasm in the Head and Neck
Preoperative Embolization of Hypervascular Head and Neck Tumors to Improve Surgical Outcomes
This phase I trial tests whether embolization done prior to surgery (preoperative) will improve surgical outcomes in head and neck tumors with large amounts of blood vessels (hypervascular).
- Trial name
- NCT05490381
- Testing
- Iodixanol, Angiogram, Arterial Embolization
- Where
- United States
- Sponsor
- University of Washington
Cervical Cancer, Fallopian Tube Cancer
Immunotoxin Therapy in Treating Patients With Advanced Cancer
RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be an effective treatment for advanced cancer.
- Conditions
- Cervical Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT00006981
- Testing
- SS1(dsFv)-PE38 immunotoxin
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Cancer
E-MOSAIC Electronic Tool to Monitor Symptoms
RATIONALE: A hand held electronic tool used to monitor symptoms and assess quality of life may improve communication between patients and their doctors and improve the ability to plan treatment for patients with advanced cancer…
- Trial name
- NCT00477919
- Where
- 7 sites in Switzerland
- Volunteers
- 264 people
- Sponsor
- Swiss Cancer Institute
Malignant Head and Neck Neoplasm
ProvoxLife Adoption Trends for Heat-Moisture Exchanger
This study examines factors that affect how often patients who have a total laryngectomy use a ProvoxLife heat-moisture exchanger (HME) system to help improve their lung function.
- Trial name
- NCT05036330
- Testing
- Clinical Evaluation, Physical Examination, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- M.D. Anderson Cancer Center
Esophageal Cancer
Use of Intra-Operative Shear Wave Ultrasound Vibrometry for Characterization of Esophageal Malignant Tumors
Using the analysis of group velocity for a screening application and then higher order analysis based on the elastic and viscious components of the shear modulus may allow discrimination between extent of tumor invasion through…
- Trial name
- NCT03211780
- Testing
- General Electric LOGIQ E9 ultrasound system
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Mayo Clinic
Esophageal Neoplasms Malignant
Multimodal Endoscopic Image Fusion for Assessing Infiltration in Superficial Esophageal Squamous Cell Carcinoma
The objective of this project is to pioneer a novel protocol for the adjunctive screening of early-stage esophageal cancer and its precancerous lesions.
- Trial name
- NCT06412419
- Testing
- Magnifying Endoscopy and Endoscopic Ultrasonography
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Changhai Hospital
Oral Potentially Malignant Disorder, Oral Cancer
The Study of p62/SQSTM1 as a Malignant Transformation Marker for Oral Potentially Malignant Disorders and a Prognostic Marker for Oral Squamous Cell Carcinoma
The mortality rate of oral cancer in Taiwan is still high with no decrease. One of the reasons result in these situations is the patent visits hospital for treatment in late stage of oral cancer.
- Conditions
- Oral Potentially Malignant Disorder, Oral Cancer, Malignant Disorder, p62/SQSTM1
- Trial name
- p62/SQSTM1 (NCT01946230)
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Esophageal Cancer
Prospective Evaluation of a New Covered Metal Stent for Malignant Lesions of the Esophagus
In this study, a newly designed and FDA approved fully covered metal stents will be used to palliate 20 patients with malignant lesion of the esophagus.
- Trial name
- NCT01301495
- Testing
- HANAROSTENT TM covered Esophageal Stent
- Where
- United States
- Sponsor
- Weill Medical College of Cornell University
Malignant Neoplasm of Thyroid Stage I, Malignant Neoplasm of Thyroid Stage II
Effect of Metformin on Decrement in Levothyroxin Dose Required for Thyroid Stimulating Hormone (TSH) Suppression in Patients With Differentiated Thyroid Cancer
Differentiated thyroid cancer is the most common neoplasm of endocrine system. After surgery and radioiodine treatment, thyroid stimulating hormone (TSH) suppression is the main goal which is achieved with levothyroxine…
- Trial name
- NCT01341886
- Testing
- Metformin
- Where
- Iran
- Volunteers
- 51 people
- Sponsor
- Mashhad University of Medical Sciences
Oral Cancer, Diagnoses Disease
Exfoliated Cytology in Detection of Oral Premalignant and Malignant Lesions
Micronuclei have been used since 1937 as an indicator of genetic toxic exposure due to their association with chromosomal alterations.
- Trial name
- NCT04955197
- Testing
- exfoliated cytology
- Where
- Egypt
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Cairo University
Radiotherapy, Metastatic Solid Cancers
Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors
Preclinical and clinical evidence suggests that intestinal low-dose radiotherapy (ILDR) may enhance antitumor immune responses by modulating the gut microenvironment, thereby improving the efficacy of immune checkpoint inhibitors…
- Conditions
- Radiotherapy, Metastatic Solid Cancers, Immune Checkpoint Blockade, Esophageal Neoplasms Malignant
- Trial name
- ILDR-02 (NCT07071103)
- Testing
- Low-dose radiotherapy to the intestine (ILDR), PD-1/PD-L1 monoclonal antibodies
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Chuangzhen Chen
Malignant Head and Neck Neoplasm
Peer Support Program for Improving Quality of Life Among Head and Neck Patients, Connecting Through Cancer Trial
This clinical trial tests whether a peer support program is feasible for head and neck cancer patients. Social support at the time of diagnosis has been shown to improve head and neck cancer quality of life before and after…
- Trial name
- NCT07664241
- Testing
- Supportive Care, Survey Administration, Interview
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- OHSU Knight Cancer Institute